Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Risk appetite is surging again Thursday on Wall Street, with investors welcoming the Federal Reserve’s decision to keep rates unchanged and F...
Moderna Inc (NASDAQ: MRNA) shares are trading lower after the company reported a deeper Q3 loss of $(9.53), down from EPS income of $2.53. The...
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
Merck & Company, Inc. (NYSE: MRK) Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion, reflecting s...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said AT&T Inc. (NYSE: T) is not his favorite. "I remain a stalwart for...
On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc (NASDAQ:COIN) amid a surge in Bitcoin (CRYPTO: B...
Moderna Inc (NASDAQ: MRNA) shares are continuing to trade lower Tuesday following Pfizer Inc's (NYSE: PFE) warning about reduced Covid-19 ...
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.&...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...